PAVmed raises $2.37M via PIPE of common stock and pre-funded warrants with Veris subsidiary shares

PAVmed Inc.

Sale of 2,574,350 shares and 756,734 pre-funded warrants at $0.7115/unit; Veris issues 677,143 shares to investors.
Gross proceeds of $2.37M; proceeds to fund Veris' implantable physiological monitor and working capital.
Company grants anti-dilution protection via additional Veris shares; restricts indebtedness until Aug 18, 2026.
Registration rights granted; stockholder vote required for warrant shares by June 30, 2025.
Transaction exempt under Section 4(a)(2) and Regulation D; no public offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.